Published November 15, 2012
Intarcia Therapeutics said it raised $210 million, enabling the biotechnology company to fund late-stage clinical trials for a new diabetes treatment without forming an alliance with a major drug maker. [ read more ]
Utah Business Social
Fast 50 Aug 27, 2015
The top 50 companies will be selected based on a combination of revenue growth and revenue gene...
PowerPoint Level 1Jul 7, 2015A hands-on, comprehensive overview of Microsoft PowerPoint. Explore the user interface and Ribbon...